Fig. 2From: Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicityComplete reponse observed in a 79 year-old male with stage IV melanoma treated with IMM-101 followed by pembrolizumab (subcutaneous disease). The subcutaneous lesions started to shrink within 4 days of the first infusion of pembrolizumabBack to article page